Crinetics Pharmaceuticals Inc (CRNX) Expected to Post Quarterly Sales of $280,000.00

Wall Street brokerages expect Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) to report sales of $280,000.00 for the current quarter, according to Zacks. Three analysts have made estimates for Crinetics Pharmaceuticals’ earnings, with estimates ranging from $250,000.00 to $300,000.00. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 29th.

According to Zacks, analysts expect that Crinetics Pharmaceuticals will report full year sales of $1.57 million for the current year, with estimates ranging from $1.50 million to $1.60 million. For the next year, analysts forecast that the firm will report sales of $440,000.00, with estimates ranging from $400,000.00 to $500,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings data on Thursday, August 30th. The company reported ($2.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($2.12). The business had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $0.09 million.

CRNX has been the subject of several analyst reports. Piper Jaffray Companies initiated coverage on shares of Crinetics Pharmaceuticals in a report on Monday, August 13th. They issued an “overweight” rating and a $40.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of Crinetics Pharmaceuticals in a report on Monday, August 13th. They issued a “neutral” rating and a $29.00 target price for the company. Leerink Swann initiated coverage on shares of Crinetics Pharmaceuticals in a report on Monday, August 13th. They issued an “outperform” rating and a $43.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, October 15th.

CRNX traded down $0.53 during trading on Wednesday, hitting $22.87. 239,175 shares of the company’s stock were exchanged, compared to its average volume of 106,787. Crinetics Pharmaceuticals has a fifty-two week low of $19.23 and a fifty-two week high of $42.00.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Read More: S&P 500 Index

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply